Merck posts two Phase 3 trials, sotatercept in HFpEF and sac-TMT in bladder cancer
Merck registered a new Phase 3 bladder cancer study and a Phase 3 sotatercept trial in heart failure, while Terns closed out two Phase 1 TERN-701 studies.
Merck's week included two newly registered Phase 3 trials and two completed early-stage studies from its Terns subsidiary.
- **MK-2870-055/TroFuse-055 (NCT07829783)**: A Phase 3 trial testing sacituzumab tirumotecan plus subcutaneous pembrolizumab alongside chemoradiotherapy in muscle-invasive bladder cancer patients who want to preserve their bladder is recruiting. The main goal of this trial is to learn if participants who receive sac-TMT, SC pembrolizumab, and CRT live longer without their cancer growing, spreading, or coming back compared to those who receive CRT alone.1 The study plans to enroll 400 participants1 and lists Event-Free Survival (EFS) as its primary outcome, measured up to approximately 60 months.1
- **MK-7962-041/CHORUS (NCT07839585)**: A Phase 3, randomized, placebo-controlled trial of sotatercept in adults with combined postcapillary and precapillary pulmonary hypertension and heart failure with preserved ejection fraction is not yet recruiting. The goal of the study is to learn if participants who receive sotatercept live longer without their CpcPH-HFpEF getting worse than those who receive placebo.2 The study plans to enroll 352 participants2 and lists Time to Clinical Worsening (TTCW) as its primary outcome2, with estimated primary completion on 2030-01-08.
- **MK-4208-001/TERN701-1014 (NCT07838987)**: A Phase 1 study of single and multiple ascending doses of TERN-701 in healthy adults, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)3, is completed. The study enrolled 196 participants (actual)3 and reached primary completion on 2026-06-30, with cohorts examining food effects, formulation comparisons, and drug interactions with rabeprazole, a probe substrate cocktail, and itraconazole.
- **MK-4208-002/TERN701-1016 (NCT07839000)**: A Phase 1, open-label mass balance study of radiolabeled TERN-701 in healthy male participants, also sponsored by Terns, a Merck subsidiary, is completed. The study enrolled 8 participants who received a single oral dose of radiolabeled TERN-7014, finishing on 2026-04-03 and tracking excretion into urine and feces alongside standard plasma pharmacokinetic measures.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.